• Bruker Acquires Minority Stake in NovAliX in Strategic Move
• Partnership Leverages Synergies Between Premium Drug Discovery CRO and High-Value Life Science Instrument Maker
• Focus on Enhancing Drug Discovery Success and Expanding NovAliX’s Footprint in the US
• Bruker Joins NovAliX and Max Planck Institute as Founding Partner of IBRB to Provide Access to Advanced Biophysics and Drug Discovery Expertise

NovAliX, a leading Contract Research Organization (CRO) specializing in drug discovery, and Bruker, a renowned provider of life science instrumentation, have entered into a strategic partnership aimed at revolutionizing drug discovery. As part of this alliance, Bruker has acquired a minority stake in NovAliX, reinforcing the crucial role CROs play in accelerating global drug research.

This collaboration seeks to enhance NovAliX’s capabilities in structural biology, biophysics, and pharmacology, combined with Bruker’s cutting-edge analytical solutions. The synergy between the two companies will help improve the efficiency of drug discovery at each stage of development.

A pivotal aspect of the partnership is the creation of the Biophysics Institute for Biomedical Research (IBRB), a new institute where NovAliX, Bruker, and the Max Planck Institute will collaborate to offer access to advanced biophysical instrumentation and drug discovery expertise. This new venture will foster innovation in therapeutic research, supporting both in-house and visiting scientists from biopharma companies globally.

Stephan Jenn, President of NovAliX, said, “This partnership with Bruker marks a significant milestone in our mission to enhance therapeutic discovery through advanced scientific capabilities. With Bruker’s support, we will expand our footprint, particularly in the US, and continue to push the boundaries of drug discovery.”

Falko Busse, President of Bruker BioSpin, added, “We are excited to collaborate with NovAliX, combining our world-class analytical technologies with their drug discovery expertise. The IBRB will be a transformative resource for researchers worldwide.”

Through this collaboration, NovAliX and Bruker aim to create next-generation drug discovery platforms that increase the success of biopharma R&D projects and contribute to the development of breakthrough therapies in key therapeutic areas such as oncology, inflammation, and genetic diseases.